A Decisional Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Naive to Iron Chelation Therapy. A Comparative Randomized Prospective Study
Phase of Trial: Phase II/III
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Deferiprone (Primary)
- Indications Beta-thalassaemia
- Focus Therapeutic Use
- 21 Jul 2017 New trial record
- 25 Jun 2017 Primary endpoint (determine the time and number of transfusion units as well as amount of infused iron that will lead to appearance of LPI > 0.2 or TSAT>50 % , serum ferritin >/= 500 ng/ml in the studied thalassemic patients which warrant start of iron chelation) has been met according to results presented at the 22nd Congress of the European Haematology Association.
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association.